Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)

4. juni 2026 oppdatert av: Ain Shams University
The aim of this study is to compare the functional visual outcomes, anatomical closure rate and macular perfusion changes assessed by OCT and OCTA after surgical repair of macular hole using Tenon capsule graft versus ILM flap.

Studieoversikt

Detaljert beskrivelse

Macular hole (MH) is a full-thickness defect of the neurosensory retina at the fovea, causing central visual loss. The incidence of idiopathic MH increases with age and is more common in females. Vitreomacular traction is the main pathophysiological factor leading to MH formation.

Pars plana vitrectomy with internal limiting membrane (ILM) peeling has been considered the standard technique for MH repair, achieving high anatomical closure rates. However, for large and refractory holes, conventional ILM peeling may not be sufficient.

The inverted ILM flap technique was developed as an alternative for large MHs (≥400 µm). This method allows the peeled ILM to be inverted and placed over the hole to serve as a scaffold for glial proliferation, enhancing closure rates and improving visual outcomes.

More recently, Tenon capsule graft has been introduced as an autologous biological scaffold for macular hole closure. Tenon tissue is rich in fibroblasts and extracellular matrix, which may promote retinal repair and facilitate closure in cases resistant to conventional approaches.

Optical coherence tomography (OCT) has become essential for evaluating macular hole dimensions, classifying stages, and confirming closure after surgery. It provides high-resolution images that allow detailed morphologic analysis.

Optical coherence tomography angiography (OCTA) enables noninvasive assessment of retinal and choroidal vasculature. Postoperative OCTA studies have shown changes in foveal avascular zone (FAZ) and vessel density in both superficial and deep plexuses, which may correlate with visual recovery.

Comparative studies between Tenon capsule graft and ILM flap using OCT and OCTA are limited, and further research is required to assess their relative efficacy in terms of anatomical closure, visual improvement, and vascular restoration. This study aims to address that gap.

The aim of this study is to compare the functional visual outcomes, anatomical closure rate and macular perfusion changes assessed by OCT and OCTA after surgical repair of macular hole using Tenon capsule graft versus ILM flap.

The study will be conducted in the ophthalmology department, at Ain Shams University Hospitals, Cairo, Egypt.

Inclusion criteria:

  • Patients diagnosed with idiopathic full-thickness macular hole
  • ≥400 µm in horizontal diameter

Exclusion criteria:

  • Media opacity preventing adequate OCT/OCTA imaging
  • Other retinal vascular pathology as retinal vascular occlusion
  • Intraoperative complications
  • Signal noise ratio using OCTA <6\10
  • Poor fixation of the patient

Group 1: Surgical repair of MH using Tenon capsule graft. Group 2: Surgical repair of MH using ILM Flap.

Sample Size:

Due to the novelty of the procedure and the rarity of cases needing surgical treatment and the expensive cost of intervention. This study is also a pilot study. This study is exempted from sample size calculation.

Study type: Prospective interventional .(Pilot study) Ethical Considerations: Written informed consent will be obtained from patients, after approval of the research ethics committee of the Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Study Tools

Preoperative examination :

All participants will have complete ocular examination including:

  • Best corrected visual acuity (BCVA) with Snellen E and then transformation to Log MAR
  • Slit-lamp examination
  • Fundus examination using 90 D lens
  • Intraocular pressure measurement by Goldmann applanation tonometry
  • Preoperative OCT to assess MH base diameter and narrowest diameter and thickness of edges to calculate MH indices
  • OCTA (OptovueInc, Fremont, CA). Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images.

Operative technique:

In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted.

In Group B: free flap ILM peeling will be attempted

SF6 gas will be used as tamponade in both groups

More than one vitreoretinal surgeon will participate

Postoperative assessment:

Patients will be examined one day and three months after surgery. Postoperative assessment will include the following with each assessment: Full ophthalmic examination (UCVA, BCVA, anterior segment assessment, Goldman applanation tonometry measurement (in all follow up visits except 1st day postoperative), fundus examination).

Postoperative OCT to assess Anatomical closure and type of closure Post-operative macular scans by OCTA (OptovueInc, Fremont, CA). Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images

Primary outcome:

  • Improvement in BCVA

Secondary outcome:

  • OCT parameters of healing and type of healing
  • OCTA parameters of macular vessel density

Statistical Analysis and Statistical Package Data will be collected and analyzed with proper statistical tests.

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Mohammad Ahmed Rashad
  • Telefonnummer: +20 111 575 8888

Studiesteder

    • Abbassia
      • Cairo, Abbassia, Egypt
        • Rekruttering
        • Ain Shams University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Patients diagnosed with idiopathic full-thickness macular hole
  • ≥400 µm in horizontal diameter

Exclusion Criteria:

  • Media opacity preventing adequate OCT/OCTA imaging
  • Other retinal vascular pathology as retinal vascular occlusion
  • Intraoperative complications
  • Signal noise ratio using OCTA <6\10
  • Poor fixation of the patient

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: ILM flap
ILM flap for treatment of macular hole as control

Prospective interventional study In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted In Group B: free flap ILM peeling will be attempted SF6 gas will be used as tamponade in both groups More than one vitreoretinal surgeon will participate

Andre navn:
  • Ilm flap
  • Tenon capsule graft
Aktiv komparator: Tenon capsule graft
Tenon capsule graft for treatment of macular hole

Prospective interventional study In all patients (Group A & B), PPV will be performed using a 23-gauge, transconjunctival, microincision vitrectomy system. Diluted triamcinolone acetonide (40 mg/ml) will be used to visualize the vitreous. After core vitrectomy, posterior hyaloid detachment will be attempted with the vitrectomy cutter in the suction mode. Then, the ILM will be stained using 0.05% Brilliant Blue G (OCUBLUE PLUS, India).

In Group A: tenon capsule graft will be attempted In Group B: free flap ILM peeling will be attempted SF6 gas will be used as tamponade in both groups More than one vitreoretinal surgeon will participate

Andre navn:
  • Ilm flap
  • Tenon capsule graft

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
-Improvement in best corrected visual acuity (BCVA)
Tidsramme: 3 months postoperative
Improvement in BCVA measured by snellen E chart then transformation to Logarithm of the minimum angle of resolution (Log MAR)
3 months postoperative

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
OCT
Tidsramme: 3 months postoperative
To assess healing and closure of hole by OCT OptovueInc, Fremont, CA (qualitative measure to assess if the hole is closed or not)
3 months postoperative
OCTA
Tidsramme: 3 months

superficial and deep capillary plexuses vessel density assessment by OCTA OptovueInc, Fremont, CA Sequential optical coherence tomography scans of a specific retinal region will be performed (central 3x3 Macular area Superficial, deep capillary plexus and choriocapillaris) and images will be processed in order to obtain motion contrast of erythrocytes within the vessel, thereby providing detailed imaging of the retinal capillary network. Capillary plexus density (CPD) of vessels in SCP, DCP and the size of the FAZ will be detected by OCTA en-face images.

(Density is measured as percentage and thickness is measured by micrometer )

3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. november 2025

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. januar 2028

Datoer for studieregistrering

Først innsendt

9. mars 2026

Først innsendt som oppfylte QC-kriteriene

4. juni 2026

Først lagt ut (Faktiske)

8. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. juni 2026

Sist bekreftet

1. mars 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere